Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 20.50 18.00 23.00 20.50 19.00 20.50 653,690 11:00:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.1 5.0 9.2 2.2 69

Summit Therapeutics plc Exercise Of Restricted Stock Units

24/12/2019 7:00am

UK Regulatory (RNS & others)


 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Exercise of Restricted Stock Units 
 
   Oxford, UK, and Cambridge, MA, US, 24 December 2019 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by 
Leopoldo Zambeletti, a Non-Executive Director of Summit, of restricted 
stock units ('RSUs') that entitled the holder to subscribe for an 
ordinary share of one penny nominal value at a subscription price of one 
penny per ordinary share. 
 
   The RSUs were granted under the Company's 2017 Remuneration Policy and 
were eligible for exercise for a limited time after completion of a 
vesting period of one year. Details of the exercise of the RSUs, all of 
which took place on 23 December 2019, and which have been duly notified 
to the Company, are summarised below. 
 
 
 
 
                                                                  % of Issued 
                                   RSU's         Shareholding        Share 
Director       Position          Exercised     (ordinary shares)    Capital 
-------------  --------------  -------------  ------------------  ------------ 
Leopoldo       Non-Executive 
 Zambeletti     Director              17,073              33,052         0.02% 
-------------  --------------  -------------  ------------------  ------------ 
 
 
   Application has been made to the London Stock Exchange for the admission 
of 17,073 ordinary shares to trading on AIM and it is expected that 
admission will become effective and that dealings will commence at 8.00 
a.m. on or around 31 December 2019. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Richard Pye (UK office)                            Tel:   +44 (0)1235 443 951 
Michelle Avery (US office)                                    +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated Adviser)   Tel:   +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
 
 
 
 
   Notification of Transactions pursuant to Article 19(1) of Regulation 
(EU) No. 596/2014 
 
 
 
 
1   Details of the persons discharging managerial responsibilities/person 
     closely associated 
    -------------------------------------------------------------------------------------- 
a)  Name                             (i) Leopoldo Zambeletti 
    ------------------------  ------------------------------------------------------------ 
2   Reason for the notification 
    -------------------------------------------------------------------------------------- 
a)  Position / status                (i) Non-Executive Director 
    ------------------------  ------------------------------------------------------------ 
b)  Initial notification /    Initial notification 
    Amendment 
    ------------------------  ------------------------------------------------------------ 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    -------------------------------------------------------------------------------------- 
a)  Name                      Summit Therapeutics plc 
    ------------------------  ------------------------------------------------------------ 
b)  LEI                       213800NRW8AOMYMTBD89 
    ------------------------  ------------------------------------------------------------ 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    -------------------------------------------------------------------------------------- 
a)  Description of the        Ordinary shares of 1 penny each 
    financial instrument, 
    type of instrument 
 
 
    Identification code       GB00BN40HZ01 
    ------------------------  ------------------------------------------------------------ 
b)  Nature of the             Exercise of restricted stock units (RSUs) to subscribe 
    transactions               for ordinary shares of one penny nominal value 
    ------------------------  ------------------------------------------------------------ 
c)  Price(s) and volume(s)      Price(s)                       Volume(s) 
    ------------------------    -----------------------------  ------------------------- 
                                (i) 1p (exercise price)           (i) 17,073 
    ------------------------    -----------------------------  ------------------------- 
 
d)  Aggregated information 
     - Aggregated volume        17,073 ordinary shares 
     - Price                    1 penny (exercise price) 
    ------------------------  ------------------------------------------------------------ 
e)  Date of the transactions  23 December 2019 
    ------------------------  ------------------------------------------------------------ 
f)  Place of the              Outside a trading venue 
    transactions 
    ------------------------  ------------------------------------------------------------ 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

December 24, 2019 02:00 ET (07:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart
Your Recent History
LSE
SUMM
Summit The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200222 08:21:56